Gene · 6571
Papers3,040
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 3,040
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of a shared blood-brain transcriptomic signature in Parkinson's disease using bioinformatic and network pharmacology approaches. | Neuroscience | 2026 | 42826760 | PubTator, text mining | PubMed |
| Molecular mechanisms of Microcystin-LR decreasing dopamine release by binding VPS35 and clinical correlation between Microcystin-LR exposure and Parkinson's disease. | J Environ Sci (China) | 2026 | 42822928 | PubTator, text mining | PubMed |
| Exploring the Potential Neurotoxic Links Between 6PPD/6PPD-Q and Parkinson's Disease Through Network Toxicology and Multi-Dimensional Bioinformatics Analysis. | Neurotox Res | 2026 | 42821203 | PubTator, text mining | PubMed |
| The mechanism underlying tardive dyskinesia: an exploratory test of the dopamine overactivity hypothesis using MRI imaging of midbrain neuromelanin. | Psychopharmacology (Berl) | 2026 | 42809103 | PubTator, text mining | PubMed |
| Stereoselectivity of pleiotropic monoamine transporter 2-benzoylpiperidine inhibitors and their potential application as novel pharmacological tools. | Biochem Pharmacol | 2026 | 42800567 | PubTator, text mining | PubMed |
| Dopaminergic Radiopharmaceutical Imaging in Parkinsonian Syndromes: From Molecular Targets to Clinical Decision-Making. | Pharmaceuticals (Basel) | 2026 | 42797415 | PubTator, text mining | PubMed |
| A Case Report: Successful Management of Mixed Tardive Syndrome With Combination Pharmacotherapy in a 19-Year-Old Female With Schizophrenia. | Clin Case Rep | 2026 | 42750933 | PubTator, text mining | PubMed |
| Neuromodulation therapies in the management of tardive dyskinesia: A scoping review. | Indian J Psychiatry | 2026 | 42725344 | PubTator, text mining | PubMed |
| Therapeutics candidates and repurposing strategies to target parkinson's disease pathology: current evidence and future directions. | Metab Brain Dis | 2026 | 42714656 | PubTator, text mining | PubMed |
| Deutetrabenazine in Hyperkinetic Movement Disorders: VMAT2 Modulation From Choreiform Disorders to Hyperkinetic Dystonic Syndromes. | J Cent Nerv Syst Dis | 2026 | 42682903 | PubTator, text mining | PubMed |
| Dopaminergic Pathway Imaging: A Visual and Educational Guide. | Neurol Clin Pract | 2026 | 42678887 | PubTator, text mining | PubMed |
| Quercetin as a Hypothesized Involvement of VMAT2 in Neurodegenerative Diseases-Mechanistic Insight and Therapeutic Applications. | Mol Neurobiol | 2026 | 42661114 | PubTator, text mining | PubMed |
| Identification of a Novel SLC18A2 Splicing Variant in a Case of Infantile Parkinsonism-Dystonia Type 2. | Case Rep Neurol Med | 2026 | 42643745 | PubTator, text mining | PubMed |
| Early glucagon-positive cells restrict pancreatic branching through VMAT2-noradrenaline-mediated ROS signaling. | Development | 2026 | 42643105 | PubTator, text mining | PubMed |
| Multimodal PET Imaging Unveils Early Metabolic Compensation Mechanisms and Dopaminergic Degeneration in Parkinson's Disease. | Cerebellum | 2026 | 42637971 | PubTator, text mining | PubMed |
| Trends in synthetic cathinone detection in seized drug samples submitted to the U.S. DEA's National Forensic Laboratory Information System, 2010-2024. | J Anal Toxicol | 2026 | 42581582 | PubTator, text mining | PubMed |
| Vesicular Monoamine Transporters at the Crossroads of Structure and Function: Advances, Challenges, and Future Perspectives. | Annu Rev Pharmacol Toxicol | 2026 | 42566692 | PubTator, text mining | PubMed |
| VMAT2 Inhibitors for Tardive Dyskinesia: What Psychiatrists Should Know. | Focus (Am Psychiatr Publ) | 2026 | 42538898 | PubTator, text mining | PubMed |
| Multitype hand writing as a digital marker for Parkinson's disease. | Clin Park Relat Disord | 2026 | 42491273 | PubTator, text mining | PubMed |
| Synaptic vesicles that store monoamines and glutamate differ in protein composition. | Sci Adv | 2026 | 42490455 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6571/papers